Among HBV‐HCC patients, ALT in the HBeAg‐ group and antiviral group was 14% lower than that in the antiviral group and HBeAg+ group (P < .05) (Figure 4B,C). This evidence concerns the gene GPT and hepatocellular carcinoma.